Email: cspc@cspc.cn
News
News Center
Jun. 13
2025
VOLUNTARY ANNOUNCEMENT - ENTERING INTO STRATEGIC RESEARCH COLLABORATION AGREEMENT WITH ASTRAZENECA
Jun. 10
VOLUNTARY ANNOUNCEMENT - SYS6040 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Jun. 05
VOLUNTARY ANNOUNCEMENT - COBAMAMIDE CAPSULES OBTAIN DRUG REGISTRATION APPROVAL
Jun. 02
JMT101 GRANTED BREAKTHROUGH THERAPY DESIGNATION IN CHINA FOR THE TREATMENT OF COLORECTAL CANCER
May. 19
JMT106 (BISPECIFIC FUSION PROTEIN DRUG) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
CPO301 GRANTED THE THIRD FAST TRACK DESIGNATION BY U.S. FDA FOR THE TREATMENT OF ADULT PATIENTS WITH NSCLC
Contact Us
Phone:
+86 311 8703 7015
Email:
cspc@cspc.cn
Products
Science
About Us
